



## Biocon Biologics in South Africa: Factsheet

**Biocon Biologics is a leading global biosimilars company committed to addressing patients' needs for cost-effective, high-quality biosimilars.**

### VISION

To be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives.

### VALUES

- Innovation & differentiation
- Quality through compliance & best practices
- Integrity and ethical behaviour
- Collaboration, teamwork and mutual respect
- Performance-driven culture

### Company Profile

**Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class 'lab to market' capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.**

In the Africa-Middle East (AFMET) region, Biocon Biologics is making a significant impact on patients' lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 6 commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing

infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune diseases through five of its products for the benefit of patients and improving healthcare outcomes in South Africa.


Headquartered in Bengaluru, India, Biocon Biologics has a longstanding presence in the biosimilars industry, having invested over \$1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics' commercial presence in South Africa. As a trusted and reliable company, Biocon Biologics is poised to grow and consolidate its leadership in biosimilars in South Africa, making a meaningful impact on patients' lives.

## The Biocon Biologics Advantage

- **PATIENT-CENTRICITY:** Committed to expand patient reach and generate significant saving for patients, payers, and healthcare systems.
- **LAB-TO-MARKET EXPERTISE:** Fully integrated from biosimilars development to manufacturing, distribution and commercialization.
- **LEGACY OF SUCCESS:** Cutting-edge scientific and technological capabilities leading to many 'firsts' in the industry - first to receive approvals in U.S. for biosimilar Trastuzumab, biosimilar Pegfilgrastim and interchangeable biosimilar Insulin Glargine.
- **UNIQUE PORTFOLIO:** Comprehensive and differentiated portfolio of biosimilars, including insulins, monoclonal antibodies, and recombinant proteins.
- **GLOBAL SCALE PRODUCTION:** Operates 3 large scale, globally compliant biosimilars manufacturing facilities; Among the Top 15\* companies globally in terms of biomanufacturing capacity.
- **WORLDWIDE COMMERCIAL FOOTPRINT:** Commercialized products in 120+ countries through a combination of direct presence, strategic partnerships and distributors.
- **PROVEN TRACK RECORD:** 80+ cGMP approvals obtained from international regulatory agencies.

\*19th Annual Report of BioPlan Associates

## QUICK FACTS



## 4A Model of Enabling Health Equity

- **Affordability:** Rationalizing treatment costs while improving healthcare outcomes.
- **Availability:** Ensuring reliable product supplies across Advanced and Emerging Markets.
- **Accessibility:** Maximizing patient reach through country-specific self and partner-led commercial models.
- **Assurance:** Establishing a trustworthy brand that stands for the highest global quality.

## Our Products in South Africa

Brand Name	Molecule
Ogivri	Trastuzumab
Abevmy	Bevacizumab
Fulphila	Pegfilgrastim
Bevamyl	Bevacizumab*
Mylan Pegfilgrastim	Pegfilgrastim*

\*Commercialized by our partner Eurolab in South Africa

## Media

### Seema Ahuja

Global Head of Corporate Brand & Head of Communications – EMs  
Email: seema.ahuja@biocon.com

## Adverse Events

### Email:

medical.informationSA@biocon.com

## Global Portfolio

Trastuzumab	Insulin Glargine
Bevacizumab	Insulin Aspart
Pegfilgrastim	Adalimumab
rh-Insulin	Etanercept

## Biocon Biologics in South Africa

### Business Partnership

#### Souhail Tebib

Commercial Head, AFMET-CIS Region  
Email: souhail.tebib@biocon.com

#### Susheel Umesh

Chief Commercial Officer, Emerging Markets  
Email: susheel.umesh@biocon.com

#### Elaine Hefer

National Sales Manager, South-Africa  
Email: elaine.hefer@biocon.com

Last updated on: September 2024

For more information:  
Biocon Biologics Corporate Factsheet  
Website: <https://www.bioconbiologics.com>

